npj Precision Oncology is a new open-access journal committed to publishing cutting edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine.
npj Precision Oncology volume 7, Article number: 134 (2023) Cite this article 2541 Accesses 1 Citations Metrics details Abstract We aimed to apply a potent deep learning network, NAFNet, to predict adverse pathology events and biochemical recurrence-free survival (bRFS) based on pre-treatment ...
npj Precision Oncology is an international, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications to clinical medicine. The journal defines precision oncology as cancer diagnosis, prognosis, preventio...
2022npj Precision Oncology doi:10.1038/s41698-022-00254-ypmid:35228642 Patients with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who are prescribed ALK-tyrosine kinase inhibitors (ALK-TKIs) rarely have complete responses, with residual tumors relapsing as heterogeneous...
documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) ...
Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using tumor gene expression profiling. Thus, we sou
Pancreatic ductal adenocarcinoma (PDAC) presents a fatal clinical challenge characterized by a dismal 5-year overall survival rate, primarily due to the lack of early diagnosis and limited therapeutic efficacy. Immunotherapy, a proven success in multiple
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology Article Open access 27 October 2022 Magnitude of effect and sample size justification in trials supporting anti-cancer drug approval by the US Food and Drug Administration Article Open access ...
Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) constitute essential components of the TME.
This study sought to elucidate the mechanisms underlying the impact of the interferon signaling pathway on Ferroptosis in tumor cells and its correlation with CD8 + T cell exhaustion. Using mouse models and single-cell sequencing, the researchers s